vs
Side-by-side financial comparison of Purple Innovation, Inc. (PRPL) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Purple Innovation, Inc. is the larger business by last-quarter revenue ($140.7M vs $103.7M, roughly 1.4× Twist Bioscience Corp). Purple Innovation, Inc. runs the higher net margin — -2.3% vs -29.4%, a 27.1% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 9.1%). Purple Innovation, Inc. produced more free cash flow last quarter ($-7.8M vs $-34.8M).
Purple Carrot is a Needham, Massachusetts-based, and 100% plant-based meal kit company. Founded by Andy Levitt, it offers both prepared meals as well as meal kits to subscribers weekly. As stated in a 2022 article in Cosmopolitan, “each Purple Carrot meal kit results in 72% less carbon being released into the atmosphere as compared to the standard American meal.”
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
PRPL vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $140.7M | $103.7M |
| Net Profit | $-3.2M | $-30.5M |
| Gross Margin | 41.9% | 52.0% |
| Operating Margin | -1.6% | -31.7% |
| Net Margin | -2.3% | -29.4% |
| Revenue YoY | 9.1% | 16.9% |
| Net Profit YoY | 62.1% | 3.4% |
| EPS (diluted) | $0.03 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $140.7M | $103.7M | ||
| Q3 25 | $118.8M | — | ||
| Q2 25 | $105.1M | — | ||
| Q1 25 | $104.2M | — | ||
| Q4 24 | $129.0M | — | ||
| Q3 24 | $118.6M | — | ||
| Q2 24 | $120.3M | — | ||
| Q1 24 | $120.0M | — |
| Q4 25 | $-3.2M | $-30.5M | ||
| Q3 25 | $-11.7M | — | ||
| Q2 25 | $-17.3M | — | ||
| Q1 25 | $-19.1M | — | ||
| Q4 24 | $-8.5M | — | ||
| Q3 24 | $-39.2M | — | ||
| Q2 24 | $27.0K | — | ||
| Q1 24 | $-50.2M | — |
| Q4 25 | 41.9% | 52.0% | ||
| Q3 25 | 42.8% | — | ||
| Q2 25 | 35.9% | — | ||
| Q1 25 | 39.4% | — | ||
| Q4 24 | 42.9% | — | ||
| Q3 24 | 29.7% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | 34.8% | — |
| Q4 25 | -1.6% | -31.7% | ||
| Q3 25 | -10.2% | — | ||
| Q2 25 | -13.5% | — | ||
| Q1 25 | -13.9% | — | ||
| Q4 24 | -6.0% | — | ||
| Q3 24 | -39.5% | — | ||
| Q2 24 | -12.1% | — | ||
| Q1 24 | -19.3% | — |
| Q4 25 | -2.3% | -29.4% | ||
| Q3 25 | -9.9% | — | ||
| Q2 25 | -16.5% | — | ||
| Q1 25 | -18.4% | — | ||
| Q4 24 | -6.6% | — | ||
| Q3 24 | -33.1% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | -41.8% | — |
| Q4 25 | $0.03 | $-0.50 | ||
| Q3 25 | $0.11 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.18 | — | ||
| Q4 24 | $0.08 | — | ||
| Q3 24 | $0.36 | — | ||
| Q2 24 | $0.00 | — | ||
| Q1 24 | $0.47 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.3M | $197.9M |
| Total DebtLower is stronger | $126.7M | — |
| Stockholders' EquityBook value | $-29.7M | $456.1M |
| Total Assets | $296.3M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.3M | $197.9M | ||
| Q3 25 | $32.4M | — | ||
| Q2 25 | $34.2M | — | ||
| Q1 25 | $21.6M | — | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $23.4M | — | ||
| Q2 24 | $23.4M | — | ||
| Q1 24 | $34.5M | — |
| Q4 25 | $126.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $70.7M | — | ||
| Q3 24 | $50.8M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-29.7M | $456.1M | ||
| Q3 25 | $-26.9M | — | ||
| Q2 25 | $-15.6M | — | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $20.2M | — | ||
| Q3 24 | $28.0M | — | ||
| Q2 24 | $66.4M | — | ||
| Q1 24 | $65.5M | — |
| Q4 25 | $296.3M | $638.1M | ||
| Q3 25 | $302.1M | — | ||
| Q2 25 | $303.8M | — | ||
| Q1 25 | $293.8M | — | ||
| Q4 24 | $307.8M | — | ||
| Q3 24 | $309.3M | — | ||
| Q2 24 | $362.1M | — | ||
| Q1 24 | $382.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.50× | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.8M | $-24.8M |
| Free Cash FlowOCF − Capex | $-7.8M | $-34.8M |
| FCF MarginFCF / Revenue | -5.5% | -33.5% |
| Capex IntensityCapex / Revenue | 1.4% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-41.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.8M | $-24.8M | ||
| Q3 25 | $-968.0K | — | ||
| Q2 25 | $-4.0M | — | ||
| Q1 25 | $-23.1M | — | ||
| Q4 24 | $6.8M | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $-8.9M | — | ||
| Q1 24 | $-16.8M | — |
| Q4 25 | $-7.8M | $-34.8M | ||
| Q3 25 | $-1.8M | — | ||
| Q2 25 | $-7.0M | — | ||
| Q1 25 | $-25.3M | — | ||
| Q4 24 | $5.7M | — | ||
| Q3 24 | $101.0K | — | ||
| Q2 24 | $-11.0M | — | ||
| Q1 24 | $-19.9M | — |
| Q4 25 | -5.5% | -33.5% | ||
| Q3 25 | -1.5% | — | ||
| Q2 25 | -6.6% | — | ||
| Q1 25 | -24.3% | — | ||
| Q4 24 | 4.4% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | -9.2% | — | ||
| Q1 24 | -16.5% | — |
| Q4 25 | 1.4% | 9.6% | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -330.22× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
